Phoebe Ashley-Norman talks with Zakiul Hassan and Prof Tahmina Shirin about the findings of "Interpreting the natural history and pathogenesis of Nipah virus disease through clinical data, to inform clinical trial design: a systematic review", by Zakiul Hassan and colleagues.

We also discuss Nipah virus disease more broadly, talking about recent phylogenetic findings, diagnostics, therapeutics, vaccines, and ongoing challenges.

Read the systematic review here: https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00223-X/fulltext

We also touched on some past Lancet publications, which you can explore here: https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(23)00361-0/fulltext https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00262-7/fulltext https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00765-5/fulltext https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00707-7/fulltext https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(24)00270-2/fulltext

Elena Dalla Vecchia talks with Claas Kirchhelle and Lloyd Czaplewski about the current antimicrobial resistance (AMR) governance (with a historical perspective on how it came to be), the 2015 WHO Global Action Plan (GAP) on AMR and the draft for the 2026 updated GAP, the role of social sciences in addressing AMR, the financing mechanisms in antibiotic research and development (including push and pull incentives with public and philantropic funding), and perspectives on the future of the fight against AMR.

Click here to read the full article:

https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00243-5/fulltext
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00216-2/fulltext

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Elisa Pucu from The Lancet Microbe interviews Dr. Magnus Unemo of Örebro University about the clinical implications and key findings from his research. They discuss about the the microbiological analysis and whole genome sequencing of treatment failures from the zoliflodacin phase 3 clinical trial for gonorrhea—revealing insights that could change the future of treatment and antibiotic resistance.

Click here to read the full articles: https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00198-3/fulltext

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01953-1/fulltext

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv